

Webcast Alert: Isis Pharmaceuticals to Provide General Corporate Update in Conjunction With 2005 Annual Meeting of Stockholders

May 19, 2005

CARLSBAD, Calif., May 19 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announces the following webcast:

What: Isis Pharmaceuticals to provide a general corporate update in conjunction with the 2005 Annual Meeting of Stockholders. The corporate update will be presented by Stanley T. Crooke, M.D., Ph.D., Chairman and Chief Executive Officer of Isis.

When: Thursday, May 26, 2005 at 1:00 PM (EDT)

Where: www.isispharm.com.

How: Live on the internet. Simply log onto either of the web sites listed above.

Contact: Claudine Prowse, Ph.D.
Director, Investor Relations and Corporate Communications
(760) 603-2331

If you are unable to participate during the live event, a replay of the webcast will be available at www.isispharm.com, under the "Investor Center" tab, for up to 30 days.

Isis Pharmaceuticals, Inc. is exploiting its expertise in RNA to discover and develop novel human therapeutic drugs for its pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 11 antisense products in development to treat metabolic, cardiovascular and inflammatory diseases, and cancer. Through its Ibis division, Isis is developing a biosensor system to identify infectious organisms. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of more than 1,500 issued patents worldwide. Additional information about Isis is available at <http://www.isispharm.com>.

SOURCE Isis Pharmaceuticals, Inc.
05/19/2005

CONTACT: Claudine Prowse, Ph.D., Director, Investor Relations and Corporate Communications of Isis Pharmaceuticals, Inc., +1-760-603-2331

Web site: <http://www.isispharm.com>
(ISIS)

05/19/2005 07:55 EDT <http://www.prnewswire.com>